Cargando…

Development of a Vaccine against SARS-CoV-2 Based on the Receptor-Binding Domain Displayed on Virus-Like Particles

The ongoing coronavirus disease (COVID-19) pandemic is caused by a new coronavirus (severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2)) first reported in Wuhan City, China. From there, it has been rapidly spreading to many cities inside and outside China. Nowadays, more than 110 milli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zha, Lisha, Chang, Xinyue, Zhao, Hongxin, Mohsen, Mona O., Hong, Liang, Zhou, Yuhang, Chen, Hongquan, Liu, Xuelan, Zhang, Jie, Li, Dong, Wu, Ke, Martina, Byron, Wang, Junfeng, Vogel, Monique, Bachmann, Martin F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073353/ https://www.ncbi.nlm.nih.gov/pubmed/33923573 http://dx.doi.org/10.3390/vaccines9040395

Ejemplares similares

Induction of Broadly Cross-Reactive Antibodies by Displaying Receptor Binding Domains of SARS-CoV-2 on Virus-like Particles
por: Chang, Xinyue, et al.
Publicado: (2022)

A Novel Double Mosaic Virus-like Particle-Based Vaccine against SARS-CoV-2 Incorporates Both Receptor Binding Motif (RBM) and Fusion Domain
por: Chang, Xinyue, et al.
Publicado: (2021)

Vaccination using mutated receptor binding domains of SARS-CoV-2: Evidence for partial immune escape but not serotype formation
por: Chang, Xinyue, et al.
Publicado: (2023)

Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
por: Vogel, Monique, et al.
Publicado: (2021)

Low‐affinity but high‐avidity interactions may offer an explanation for IgE‐mediated allergen cross‐reactivity
por: Chang, Xinyue, et al.
Publicado: (2021)

Virus-Like Particles Are Efficient Tools for Boosting mRNA-Induced Antibodies
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

TLR7 Signaling Shapes and Maintains Antibody Diversity Upon Virus-Like Particle Immunization
por: Chang, Xinyue, et al.
Publicado: (2022)

SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
por: Bachmann, Martin F., et al.
Publicado: (2021)

AP205 VLPs Based on Dimerized Capsid Proteins Accommodate RBM Domain of SARS-CoV-2 and Serve as an Attractive Vaccine Candidate
por: Liu, Xuelan, et al.
Publicado: (2021)

BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced
por: Chang, Xinyue, et al.
Publicado: (2021)

Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System
por: Mohsen, Mona O., et al.
Publicado: (2018)

In vitro data suggest that Indian delta variant B.1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
por: Augusto, Gilles, et al.
Publicado: (2021)

Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2022)

Special Issue “Virus-Like Particle Vaccines”
por: Vogel, Monique, et al.
Publicado: (2020)

A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
por: Mohsen, Mona O., et al.
Publicado: (2021)

Virus-like particle vaccinology, from bench to bedside
por: Mohsen, Mona O., et al.
Publicado: (2022)

Therapeutic silence of pleiotrophin by targeted delivery of siRNA and its effect on the inhibition of tumor growth and metastasis
por: Zha, Lisha, et al.
Publicado: (2017)

Virus‐like particles for vaccination against cancer
por: Mohsen, Mona O., et al.
Publicado: (2019)

SARS-CoV-2 receptor binding domain displayed on HBsAg virus–like particles elicits protective immunity in macaques
por: Dalvie, Neil C., et al.
Publicado: (2022)

The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics”
por: Mohsen, Mona O., et al.
Publicado: (2020)

Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
por: Brune, Karl D., et al.
Publicado: (2016)

A Novel Bacterium-Like Particle Vaccine Displaying the MERS-CoV Receptor-Binding Domain Induces Specific Mucosal and Systemic Immune Responses in Mice
por: Li, Entao, et al.
Publicado: (2019)

Novel chimeric virus-like particles vaccine displaying MERS-CoV receptor-binding domain induce specific humoral and cellular immune response in mice
por: Wang, Chong, et al.
Publicado: (2017)

Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2019)

On the complexity of IgE: The role of structural flexibility and glycosylation for binding its receptors
por: Plattner, Kevin, et al.
Publicado: (2023)

Neutralization of MERS coronavirus through a scalable nanoparticle vaccine
por: Mohsen, Mona O., et al.
Publicado: (2021)

Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine
por: Kumar, Kiven, et al.
Publicado: (2023)

Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2023)

Correction: Zika Virus-Derived E-DIII Protein Displayed on Immunologically Optimized VLPs Induces Neutralizing Antibodies without Causing Enhancement of Dengue Virus Infection. Vaccines 2019, 7, 72
por: Cabral-Miranda, Gustavo, et al.
Publicado: (2020)

On Iron Metabolism and Its Regulation
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2021)

VisProDom: an interactive Shiny/R application for displaying protein domains with transcriptional features
por: Wang, Hongwei, et al.
Publicado: (2022)

Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2
por: Arora, Upasana, et al.
Publicado: (2012)

Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice
por: Yang, Ming, et al.
Publicado: (2017)

Anti-IAPP Monoclonal Antibody Improves Clinical Symptoms in a Mouse Model of Type 2 Diabetes
por: Vogt, Anne-Cathrine S., et al.
Publicado: (2021)

Structural analysis and insertion study reveal the ideal sites for surface displaying foreign peptides on a betanodavirus-like particle
por: Xie, Junfeng, et al.
Publicado: (2016)

Immunogenic Subviral Particles Displaying Domain III of Dengue 2 Envelope Protein Vectored by Measles Virus
por: Harahap-Carrillo, Indira S., et al.
Publicado: (2015)

Virus-like particles (VLP) in prophylaxis and immunotherapy of allergic diseases
por: Klimek, Ludger, et al.
Publicado: (2018)

Particle identification as currently implemented in "DISPLAY"
por: Ferro-Luzzi, Massimiliano
Publicado: (1994)

More than one way to bind to cholesterol: atypical variants of membrane-binding domain of perfringolysin O selected by ribosome display
por: Šakanović, Aleksandra, et al.
Publicado: (2020)

Exploring the Landscape of the PP7 Virus-like Particle for Peptide Display
por: Keshavarz-Joud, Parisa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3r50quk6jitkrgqoonimvguoss